BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 15450340)

  • 1. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety.
    Yamauchi PS; Gindi V; Lowe NJ
    Dermatol Clin; 2004 Oct; 22(4):449-59, ix. PubMed ID: 15450340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept for psoriasis in the pediatric population: experience in nine patients.
    Hawrot AC; Metry DW; Theos AJ; Levy ML
    Pediatr Dermatol; 2006; 23(1):67-71. PubMed ID: 16445417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.
    De Felice C; Mazzotta A; Esposito M; Bianchi L; Chimenti S
    J Dermatolog Treat; 2006; 17(6):355-8. PubMed ID: 17853309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
    Strober BE; Clarke S
    J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab.
    Strober BE
    Arch Dermatol; 2004 Mar; 140(3):366. PubMed ID: 15023789
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients.
    Campione E; Mazzotta A; Paternò EJ; Diluvio L; Prinz JC; Chimenti S
    Acta Derm Venereol; 2009; 89(3):288-91. PubMed ID: 19479128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept for psoriasis: two case reports.
    Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
    Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
    Krueger GG; Elewski B; Papp K; Wang A; Zitnik R; Jahreis A
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S112-9. PubMed ID: 16488321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis.
    Thayer S; Watson C; Song R; Globe DR; Harrison DJ
    J Med Econ; 2010; 13(2):228-35. PubMed ID: 20459298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Puerto Rico psoriasis study group: efficacy and safety of etanercept.
    González-Chavez JR; Berlingeri-Ramos AC; Sánchez Casiano MA
    J Drugs Dermatol; 2005; 4(6):735-9. PubMed ID: 16302559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
    de Vlam K; Lories RJ
    Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept therapy in patients with autoimmunity and hepatitis C.
    Khanna M; Shirodkar MA; Gottlieb AB
    J Dermatolog Treat; 2003 Dec; 14(4):229-32. PubMed ID: 14660270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept for the treatment of psoriasis.
    Bissonnette R
    Skin Therapy Lett; 2006 Feb; 11(1):1-4. PubMed ID: 16485060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P; Del Giglio M; Cotena C; Girolomoni G
    Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.